📊 PFE Key Takeaways
Is Pfizer Inc. (PFE) a Good Investment?
Pfizer demonstrates operational strength with healthy 21.9% operating margins and solid free cash flow generation of $2.2B, but is hindered by declining revenue (-1.6% YoY), stalled net income growth, and critically poor capital efficiency reflected in 3.0% ROE and 1.3% ROA. High debt burden combined with low cash reserves and weak quick ratio create vulnerability despite operational profitability.
Why Buy Pfizer Inc. Stock? PFE Key Strengths
- Strong operating margin of 21.9% and net margin of 18.6% demonstrate pricing power and operational efficiency
- Positive free cash flow of $2.2B with 15.1% FCF margin provides financial flexibility and dividend capacity
- Moderate debt-to-equity ratio of 0.67x and interest coverage of 4.7x indicate manageable debt service obligations
PFE Stock Risks: Pfizer Inc. Investment Risks
- Revenue declining 1.6% YoY with flat net income growth and declining EPS (-3.5%) signals top-line pressure and margin compression
- Extremely poor capital efficiency with ROE of 3.0% and ROA of 1.3% indicates significant capital destruction despite operational profitability
- High debt load of $60.6B relative to minimal cash position of $1.7B and quick ratio below 1.0 (0.94x) constrains financial flexibility
Key Metrics to Watch
- Revenue growth trajectory and return to positive growth
- Return on equity improvement path - currently unacceptable at 3.0%
- Cash position and debt reduction strategy relative to operational cash flow
Pfizer Inc. (PFE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Pfizer Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
PFE Profit Margin, ROE & Profitability Analysis
PFE vs Healthcare Sector: How Pfizer Inc. Compares
How Pfizer Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Pfizer Inc. Stock Overvalued? PFE Valuation Analysis 2026
Based on fundamental analysis, Pfizer Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Pfizer Inc. Balance Sheet: PFE Debt, Cash & Liquidity
PFE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Pfizer Inc.'s revenue has grown significantly by 71% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.37 reflects profitable operations.
PFE Revenue Growth, EPS Growth & YoY Performance
PFE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $13.7B | $2.7B | $0.47 |
| Q3 2025 | $16.7B | $3.5B | $0.62 |
| Q2 2025 | $13.3B | $41.0M | $0.01 |
| Q1 2025 | $13.7B | $3.0B | $0.52 |
| Q3 2024 | $13.5B | -$2.4B | $-0.42 |
| Q2 2024 | $13.0B | $41.0M | $0.01 |
| Q1 2024 | $14.9B | $3.1B | $0.55 |
| Q3 2023 | $13.2B | -$2.4B | $-0.42 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Pfizer Inc. Dividends, Buybacks & Capital Allocation
PFE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Pfizer Inc. (CIK: 0000078003)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PFE
What is the AI rating for PFE?
Pfizer Inc. (PFE) has an AI rating of HOLD with 60% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PFE's key strengths?
Claude: Strong operating margin of 21.9% and net margin of 18.6% demonstrate pricing power and operational efficiency. Positive free cash flow of $2.2B with 15.1% FCF margin provides financial flexibility and dividend capacity.
What are the risks of investing in PFE?
Claude: Revenue declining 1.6% YoY with flat net income growth and declining EPS (-3.5%) signals top-line pressure and margin compression. Extremely poor capital efficiency with ROE of 3.0% and ROA of 1.3% indicates significant capital destruction despite operational profitability.
What is PFE's revenue and growth?
Pfizer Inc. reported revenue of $14.5B.
Does PFE pay dividends?
Pfizer Inc. does not currently pay dividends.
Where can I find PFE SEC filings?
Official SEC filings for Pfizer Inc. (CIK: 0000078003) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PFE's EPS?
Pfizer Inc. has a diluted EPS of $0.47.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PFE a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Pfizer Inc. has a HOLD rating with 60% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PFE stock overvalued or undervalued?
Valuation metrics for PFE: ROE of 3.0% (sector avg: 15%), net margin of 18.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PFE stock in 2026?
Our dual AI analysis gives Pfizer Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is PFE's free cash flow?
Pfizer Inc.'s operating cash flow is $2.6B, with capital expenditures of $436.0M. FCF margin is 15.1%.
How does PFE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 18.6% (avg: 12%), ROE 3.0% (avg: 15%), current ratio 1.25 (avg: 2).